Back to search

Article

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patients

2022-03-24

Abstract excerpt

<h4>Background: </h4> The clinical implication of circulating tumor DNA (ctDNA) as a prognostic or predictive biomarker in DLBCL patients receiving standard immunochemotherapy is uncertain. <h4>Methods: </h4>: Here, using targeted next-generation sequencing, we assessed the prognostic and predictive utility of ctDNA in 73 DLBCL patients before, during and after the first line therapy <h4>Results: </h4>: Pretreatme...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cf8a057c-8bcb-56ed-9f13-be712b02a825
DOI
10.21203/rs.3.rs-1478293/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patientsDOI 10.21203/rs.3.rs-1478293/v1
Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity
Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity
The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity
Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.Semantic proximity
[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].Semantic proximity
The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity
[Progression and application of circulating tumor DNA in lymphoma].Semantic proximity
Circulating tumour DNA in B‐cell lymphomas: current state and future prospectsSemantic proximity
Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas.Semantic proximity
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaSemantic proximity
Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.Semantic proximity
Select a neighboring publication to make it the new centre.